Pfizer (Netherlands)

Recent papers from Pfizer (Netherlands)

1. Dynamic Medicine Prices for Health-Economic Analyses in the Netherlands: A Case for Integrating Pre- and Post-Exclusivity Price DynamicsJournal of Market Access & Health Policy · 2026
2. Analysis of the Azimuthal Dependency of HVSR in Complex 3D Velocity Structures Using Numerical ModelingBulletin of the Seismological Society of America · 2026
3. Residual Disparities in US Adults Hospitalized due to All-Cause Pneumonia Following Implementation of Childhood 13-Valent Pneumococcal Conjugate Vaccine in National Immunization ProgramOpen Forum Infectious Diseases · 2026
4. Residual Disparities in US Children Hospitalized Due to All-Cause Pneumonia Following Implementation of Childhood PCV13 in National Immunization ProgramVaccines · 2026
5. Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Prefusion F Vaccine for Older Adults in the NetherlandsInfectious Diseases and Therapy · 2026
6. Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in the 20-Valent Pneumococcal Conjugate Vaccine in the Adult Population in FranceOpen Forum Infectious Diseases · 2026
7. Projected health and economic impact of PCV20 vaccination in UK children: a dynamic transmission model2026
8. Correction: Dawson et al. A Multi-Country Comparison of Number Needed to Vaccinate for PCV20 and PCV15 in Infants. Vaccines 2026, 14, 188Vaccines · 2026
9. A Multi-Country Comparison of Number Needed to Vaccinate for PCV20 and PCV15 in InfantsVaccines · 2026
10. P-1571. Variability in Case-Ascertainment Methodology and Rates of Adult Invasive Pneumococcal Disease using a US Healthcare Claims DatabaseOpen Forum Infectious Diseases · 2026
11. P-555. Temporal Trends in Rates of Hospitalized Pneumonia among US Adults and Residual Disparities by Race and Socioeconomic StatusOpen Forum Infectious Diseases · 2026
12. P-1456. Re-evaluating Economic & Health Impact of PCV20 in Adults Using Real-world Effectiveness DataOpen Forum Infectious Diseases · 2026
13. P-1429. Uptake and Series Completion with Pneumococcal Conjugate Vaccine by Social Determinants of Health among Children in the United StatesOpen Forum Infectious Diseases · 2026
14. Preferences of Dutch Parents and Expectant Parents for Respiratory Syncytial Virus Prevention Strategies: A Discrete Choice ExperimentInfectious Diseases and Therapy · 2025
15. Disparities in invasive pneumococcal disease, pneumonia, and otitis media among US children by comorbidity profile and insurance statusFrontiers in Public Health · 2025
16. Identification of distinct disease activity trajectories in patients with psoriatic arthritis receiving tofacitinib: a post hoc analysis of two phase 3 studiesRMD Open · 2025
17. Cost of invasive pneumococcal disease, all-cause pneumonia, and all-cause otitis media among commercial-insured US childrenJournal of Medical Economics · 2025
18. JAK inhibition and axial spondyloarthritis: new steps on the path to understanding pathophysiologyFrontiers in Immunology · 2025
19. Cost-effectiveness of nirmatrelvir/ritonavir in COVID-19 patient groups at high risk for progression to severe COVID-19 in the NetherlandsCost Effectiveness and Resource Allocation · 2025
20. Economic Evaluation of Transitioning to the 20-Valent Pneumococcal Conjugate Vaccine in the Dutch Paediatric National Immunisation ProgrammeSHILAP Revista de lepidopterología · 2025